Artemis Medicare Services Ltd

Financial Performance

• Consolidated revenue for Q1 FY27: INR 287.32 crores, up 12.7% YoY.
• Standalone Gurgaon revenue grew 15.4% YoY.
• EBITDA for Q1: INR 61.82 crores, margin 21.5%.
• PAT for Q1: INR 31.44 crores, up 48.3% YoY.

Operational Update

• Gurugram occupancy 65.7%, ARPOB INR 85,690.
• Raipur 300-bed hospital commenced operations; OPD July 9; theatres and cath labs July 27.
• International patients accounted for ~27% of international business in Q1.

Capex and Projects

• Tower IV Gurgaon: 200+ beds, 18–22 months to full operation.
• Total bed capacity target: 2,000 by 2029‑2030.
• Capex over next three years ~INR 800 crores; Raipur ~INR 120 crores; VIMHANS ~INR 350–360 crores.
• Tower IV capex per bed ~INR 55 lakhs; 200 beds.

Guidance and Outlook

• Raipur insurance empanelment expected in 8–10 weeks; cashless intermediaries in place till then.
• Raipur ramp-up expected 20–25% faster post-empanelment.
• QIP of INR 700 crores enabling expansion; timeline 6–8 months to proceed.

Q&A Highlights

• Gurgaon margins expected to be 23%+ in 2–3 years.
• Raipur break-even in 15–18 months; initial ~INR 20 crores operating loss.
• Daffodils hub-and-spoke consolidation for efficiency; ongoing expansion plans.
• Gurgaon occupancy to reach 50% in six months (management view).
• Post-expansion bed count around 900–960; occupancy target 70%–72%; potential 23%+ margins.

Meeting Details

• Date: Thursday, August 13, 2026
• Time: not disclosed
• Type/Mode: Group investor conference, in-person
• Event/Organizer: EMKAY Confluence 2026—Annual Investor Conference
• Location: Mumbai

Participants

• Company representatives: Company Secretary and Compliance Officer

Purpose

• Purpose: Investor interaction at annual conference

Meeting Details

• Date: August 13, 2026; Time: not specified.
• Event: EMKAY Confluence 2026: 'India: Full Throttle Ahead'; Investor conference.
• Location: Mumbai; Mode: Physical.
• Purpose: investor conference participation by company representatives.
• Key participants: company representatives (management).

Independent Director Appointment

• Appointment of Dr. Girdhar Jessaram Gyani as Independent Director for 3 years.
• Effective from 1 August 2026 to 31 July 2029.
• Reason: appointment approved by the 22nd AGM.
• Profile: healthcare veteran; AHPI Director General; former NABH CEO.
• Relationship: no relationship with other directors disclosed.
• Not debarred by SEBI or other authorities.

AGM Details

• Date and time: 31 July 2026 at 3:00 PM IST; mode: VC/OAVM.
• Cut-off for voting: 24 July 2026; shareholders on cut-off: 37,435.
• Attendance via VC: Promoter Group 2; Public 84.

Dividend

• Final dividend of Re 0.45 per equity share for FY2026.

Key Resolutions & Outcomes

• Resolution 1 (Ordinary): Adopt audited standalone and consolidated statements for FY2026 — passed.
• Resolution 2 (Ordinary): Declare final dividend of Re 0.45 per share — passed.
• Resolution 3 (Ordinary): Re-appoint Shalini Kanwar Chand (rotating) — passed.
• Resolution 4 (Ordinary): Re-appoint TR Chadha & Co LLP as statutory auditors — passed.
• Resolution 5 (Ordinary): Ratify remuneration to Cost Auditors for 2026-27 — passed.
• Resolution 6 (Special): Appoint Mr. Tapan Mitra as Independent Director — passed.
• Resolution 7 (Special): Appoint Dr. Girdhar Jessaram Gyani as Independent Director — passed.
• Resolution 8 (Ordinary): Remuneration by way of commission to Non-Executive Directors — passed.

Directors & Auditors

• Appointments: Independent Directors Tapan Mitra and Dr. Girdhar Jessaram Gyani.
• Re-appointment: Shalini Kanwar Chand as director.
• Auditors: TR Chadha & Co LLP re-appointed as statutory auditors.

AGM Details

• AGM held on July 31, 2026 at 3:00 PM IST via Video Conferencing.
• Record date for dividend: July 10, 2026.

Ordinary Business

• Adoption of standalone and consolidated financial statements for the financial year ended March 31, 2026.
• Declaration of final dividend of Re 0.45 per equity share for FY2026.
• Re-appointment of Ms. Shalini Kanwar Chand as Director liable to retire by rotation.
• Re-appointment of M/s TR Chadha & Co LLP as Statutory Auditors for five-year term to 2031.

Special Business

• Ratification of remuneration to Cost Auditors for FY 2026-27.
• Appointment of Mr. Tapan Mitra as Independent Director for 3 years (May 8, 2026–May 7, 2029).
• Appointment of Dr. Girdhar Jessaram Gyani as Independent Director for 3 years (Aug 1, 2026–Jul 31, 2029).
• Remuneration by way of commission to Non-Executive Directors.

Voting & Results

• Voting results not disclosed in the document; chairman to declare results later.

Meeting Details

• Date and time: 4 August 2026 at 11:00 AM IST.
• Type and mode: virtual group earnings conference call.
• Organizer: Hosted by Anand Rathi Research.
• Key company participants: Chief Financial Officer, Managing Director, Head - Investor Relations, M&A and Organization Growth Strategy.
• Purpose: discuss Q1 FY27 operational and financial performance.

Meeting Details

• Earnings conference call for Q1 FY27 scheduled for 4 August 2026 at 11:00 AM IST.
• Hosted by Anand Rathi Research.

Participants

• Key company participants: CFO, Managing Director, Head of Investor Relations (M&A and Organization Growth Strategy).

Purpose

• Purpose: discuss operational and financial performance for Q1 FY27 with investors and analysts.

Meeting Details

• Meeting on Aug 3, 2026 to consider unaudited standalone and consolidated results for quarter ended June 30, 2026.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated results for quarter ended June 30, 2026.

Other Notes

• Trading window closed from July 1, 2026 until 48 hours after results declaration (up to Aug 5, 2026).